Table 5.

Outcome of transplantation (N = 6)

Patient	Transplant	Age at transplantation	Time after first presentation of aHUS	HLA mismatch	Treatment before transplantation	Induction immunosuppression	Maintenance immunosuppression	Outcome
4a	DCD (en bloc)	8 yr, 9 mo	5 yr	Unknown	None	Unknown	Unknown	Primary nonfunction
4a	LRTb ABOi	9 yr, 3 mo	5 yr, 6 mo	1:1:1	Rituximab and immunoadsorptionc	Basiliximab	Tacrolimus, MMF, prednisolone	Immediate recurrence,d eculizumab, creatinine: 72 μmol/l, eGFR: 47.6 ml/min per 1.73 m2 (follow-up 9 mo)
5	DBD	12 yr, 6 mo	1 yr, 10 mo	1:1:0	None	Basiliximab	Tacrolimus, azathioprine, prednisolone	Transplant failed after 7 yr 6 mo (severe AMR postpartum)
12	DBD	10 yr	1 yr, 5 mo	Unknown	None	Basiliximab	MMF, prednisolone	Creatinine: 80 μmol/l, eGFR: >60 ml/min per 1.73 m2 (follow-up 6 yr 9 mo)
19	DBD	11 yr, 5 mo	1 yr, 5 mo	1:1:0	None	Unknown	Tacrolimus, azathioprine, prednisolone	Creatinine: 109 μmol/l, eGFR: 48.4 ml/min per 1.73 m2 (follow-up: 3 yr 11 mo)
22	DCD	9 yr, 9 mo	2 yr	Unknown	None	Basiliximab	Tacrolimus (purine antagonist stopped)	Creatinine: 83 μmol/l, eGFR: >60 ml/min per 1.73 m2 (follow-up: 2 yr 5 mo)

ABOi, ABO incompatible; aHUS, atypical hemolytic uremic syndrome; AMR, antibody-mediated rejection; DBD, donor after brain death; DCD, donor after cardiac death; eGFR, estimated glomerular filtration rate; LRT, living related transplant; MMF, mycophenolate mofetil.

eGFR by Schwartz formula (all patients were younger than 18 years of age at last follow-up).

^aConcomitant functionally significant CFI mutation.

^bLRT: living donor underwent genetic screening; no rare genetic variant, 0 copies CFHR1, 1 copy CFHR3.

^cTreatment given because of ABO incompatibility: rituximab 1 month before transplant, and immunoadsorption ×4 (anti–A titers reduced from 1:128 to 1:8).

^dRecurrence 9 hours after transplantation. Successfully treated with eculizumab.